USV Launches Jalra Trio for Management of Type 2 Diabetes in India MD Brand Connect11 Aug 2023 12:22 PM ISTUSV Pvt. Ltd, a leading drug manufacturer in the anti-diabetic segment, has announced the launch of the brand Jalra Trio for the treatment of...
New products, nutraceuticals added under Jan Aushadhi Pariyojana Ruchika Sharma30 July 2023 10:00 AM ISTThe product basket of Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) has 1800 medicines, 285 Surgical Equipment and Consumables.
Dapagliflozin use linked to sarcopenia in non obese patients of type 1 diabetes Dr. Kamal Kant Kohli29 July 2023 11:30 AM ISTDapagliflozin treatment of individuals with type 1 diabetes, particularly non-obese individuals and older men, might result in loss of skeletal muscle...
Dapagliflozin not better than metolazone at relieving congestion in HF patients with loop diuretic resistance Dr. Kamal Kant Kohli19 July 2023 9:15 AM ISTA recent study published in European Heart Journal showed a randomized trial comparing the sodium-glucose cotransporter 2 (SGLT2) inhibitor...
AstraZeneca Xigduo XR approved in China for adults with type 2 diabetes Ruchika Sharma28 Jun 2023 4:30 PM ISTChina: AstraZeneca’s Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, has been approved by...
Dapagliflozin, a feasible alternative to sulphonylureas as an add-on after metformin failure in type 2 diabetes patients Medha Baranwal24 Jun 2023 11:15 AM ISTKorea: Dapagliflozin is safe and well-tolerated and, therefore, appears to be a more favourable alternative to sulphonylureas as an add-on therapy...
Dapagliflozin therapy not linked to renal damage in heart failure patients Jacinthlyn Sylvia14 Jun 2023 9:45 AM ISTA new study by Nakase and team showed that patients with heart failure with a reduced ejection fraction (HFrEF) who saw a brief drop in estimated...
Alkem Gets CDSCO Panel Nod To Manufacture, Market Linagliptin, Dapagliflozin antidiabetic FDC Dr. Divya Colin2 Jun 2023 6:00 PM ISTNew Delhi: The drug major Alkem Health Sciences has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug...
Novel triple-drug FDC superior to dual combination in type 2 diabetes patients poorly controlled with metformin Medha Baranwal2 Jun 2023 11:30 AM ISTIndia: A recent study has shown a triple-drug fixed-dose combination (FDC) of sitagliptin + dapagliflozin + metformin ER to be superior to dual...
AstraZeneca gets CDSCO panel nod to Market Dapagliflozin to treat heart failure in adult Dr. Divya Colin31 May 2023 6:00 PM ISTNew Delhi: Pharmaceutical major, AstraZeneca has got a go-ahead from the Subject Expert Committee (SEC) functional under Central Drug Standard Control...
Glenmark gets CDSCO panel nod for Phase III CT of antidiabetic FDC drug Dr. Divya Colin20 May 2023 6:00 PM ISTNew Delhi: Considering the drug major Glenmark's request for bioequivalence (BE) study waiver, the Subject Expert Committee (SEC) functional under...
AstraZeneca Farxiga approved in US to reduce risk of cardiovascular death, hospitalisation for heart failure to broader range of patients Ruchika Sharma10 May 2023 12:30 PM ISTCambridge: AstraZeneca has announced that Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death,...
